excerpts:

Chinese vaccine producer CanSino’s single-dose COVID-19 vaccine Ad5-nCoV showed 90.98 percent efficacy rate in preventing severe disease in interim analysis, and is effective to prevent 65.7 percent of symptomatic diseases in clinical trials conducted in multiple countries including Pakistan

The interim analysis in Pakistan showed 100 percent efficacy at preventing severe disease, and 74.8 percent for symptomatic diseases

No severe adverse cases related to the vaccine had occurred in trials across the world.

It did not report any serious safety concerns in the trials that finally found 101 confirmed COVID-19 cases among 30,000 volunteers in the placebo-controlled trials.

“A 70 percent effective single-dose vaccine may be more valuable than a two-dose regimen with 90 percent efficacy,” the WHO Ad-hoc Expert Group previously said in the New England Journal of Medicine. Under the same efficacy rate and capacity conditions, the single-shot vaccine doubles the amount of people being immunized.

“The single dose can vaccinate as many people as possible in the short term compared to traditional two-dose inactivated vaccines. Moreover, it relieves the pressure on production capacity and reduces the cost of administration and transportation,” Shanghai-based vaccine observer Tao Lina told the Global Times on Monday.